X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sangamo anticipates using the net proceeds to fund the development of neurology-focused genomic medicines pipeline, including its zinc finger transcriptional repressor targeting the SCN9A gene as a novel therapy for peripheral neuropathic pain.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Barclays
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 22, 2024
Details:
STAC-BBB is company's proprietary novel neurotropic adeno-associated virus (AAV) capsid, whixh showed blood-brain barrier penetration and brain transduction in preclinical studies. It is being evauated for the treatment of prion disease and tauopathy.
Lead Product(s): STAC-BBB
Therapeutic Area: Neurology Product Name: STAC-BBB
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
ST-920 (isaralgagene civaparvovec) is a liver-tropic rAAV 2/6 vector carrying the cDNA for human α-Gal A. It is being developed for the treatment of Fabry Disease.
Lead Product(s): Isaralgagene Civaparvovec
Therapeutic Area: Genetic Disease Product Name: ST-920
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
ST-920 (isaralgagene civaparvovec) is a liver-tropic rAAV 2/6 vector carrying the cDNA for human α-Gal A. It is being evaluated in phase 1/2 clinical trials for the treatment of Fabry Disease.
Lead Product(s): Isaralgagene Civaparvovec
Therapeutic Area: Genetic Disease Product Name: ST-920
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
Under the terms of the agreement, Chroma will evaluate novel Sangamo zinc finger proteins (ZFPs) for specified collaboration targets outside of the central nervous system, for the development of epigenetic medicines.
Lead Product(s): Epigenetic Medicine
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chroma Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 20, 2023
Details:
Under the agreement, Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.
Lead Product(s): Adeno-associated Virus Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Prevail Therapeutics
Deal Size: $1,190.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 17, 2023
Details:
Under the terms of the agreement, Sangamo has received a non-exclusive license to combine a Voyager TRACER capsid with Sangamo’s ZF-TRs (zinc finger transcriptional regulator) designed to treat prion disease.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Voyager Therapeutics, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 29, 2023
Details:
ST-920 (isaralgagene civaparvovec) is a liver-tropic rAAV 2/6 vector carrying the cDNA for human α-Gal A that aims to deliver a working copy of the GLA gene to the liver so that liver cells can start producing functional α-Gal A in patients with fabry disease.
Lead Product(s): Isaralgagene Civaparvovec
Therapeutic Area: Genetic Disease Product Name: ST-920
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
ST-920 (isaralgagene civaparvovec) is a liver-tropic rAAV 2/6 vector carrying the cDNA for human α-Gal A that aims to deliver a working copy of the GLA gene to the liver so that liver cells can start producing functional α-Gal A in patients with fabry disease.
Lead Product(s): Isaralgagene Civaparvovec
Therapeutic Area: Genetic Disease Product Name: ST-920
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
ST-920 (Isaralgagene civaparvovec) requires a one-time infusion without preconditioning. The STAAR study is enrolling patients who are on ERT, are ERT pseudo-naïve (defined as having been off ERT for six or more months), or who are ERT-naïve.
Lead Product(s): Isaralgagene Civaparvovec
Therapeutic Area: Genetic Disease Product Name: ST-920
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
